Stockreport

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcino [Read more]